Literature DB >> 23203167

Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.

Robert P L Wisse1, Dienke Wittebol-Post, Gepke Visser, Allegonda van der Lelij.   

Abstract

We present a 17-year-old boy, diagnosed with tyrosinaemia type I at an age of 7 months, with new complaints of severe intermittent photophobia and burning eyes. His tyrosinaemia type I is treated with nitisinone and a protein-restricted diet. Dietary compliance is low since he entered puberty. His ocular complaints are attributable to subepithelial corneal deposits, resembling the common corneal phenotype of tyrosinaemia type II. Serum tyrosine levels were markedly elevated. Tyrosinaemia is a metabolic disease of tyrosine metabolism, subdivided into two types. Corneal deposits and photophobia are cardinal features of untreated tyrosinaemia type II, but not of type I. Novel treatment strategies (with nitisinone) for type I tyrosinaemia lead to a phenotype comparable with type II, including these corneal deposits. At follow-up visits his ocular complaints unfortunately remained unchanged, though he states his dietary compliance improved through the years.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23203167      PMCID: PMC4543320          DOI: 10.1136/bcr-2012-006301

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Corneal opacities associated with NTBC treatment.

Authors:  Saad Ahmad; Jeffrey H Teckman; Gregg T Lueder
Journal:  Am J Ophthalmol       Date:  2002-08       Impact factor: 5.258

3.  Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Authors:  P Gissen; M A Preece; H A Willshaw; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

4.  NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

Authors:  A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati
Journal:  J Inherit Metab Dis       Date:  2008-01-25       Impact factor: 4.982

5.  The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.

Authors:  E A Lock; P Gaskin; M K Ellis; M Robinson; W M Provan; L L Smith
Journal:  Toxicol Appl Pharmacol       Date:  1998-05       Impact factor: 4.219

  5 in total
  4 in total

1.  Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Authors:  Yue Tang; Yuanyuan Kong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

2.  Treatment Adherence in Type 1 Hereditary Tyrosinaemia (HT1): A Mixed-Method Investigation into the Beliefs, Attitudes and Behaviour of Adolescent Patients, Their Families and Their Health-Care Team.

Authors:  Sumaira Malik; Sinead NiMhurchadha; Christina Jackson; Lina Eliasson; John Weinman; Sandrine Roche; John Walter
Journal:  JIMD Rep       Date:  2014-09-12

3.  Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles.

Authors:  Hao Yang; Francis Rossignol; Denis Cyr; Rachel Laframboise; Shu Pei Wang; Jean-François Soucy; Marie-Thérèse Berthier; Yves Giguère; Paula J Waters; Grant A Mitchell
Journal:  Mol Genet Metab Rep       Date:  2017-12-27

Review 4.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.